Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE